27 Ago Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir ± ribavirin in HIV/HCV co-infected patients

This work examined the trend of the estimated glomerular filtration rate (eGFR) of patients included in the SIMIT compassionate use program of ombitasvir/paritaprevir/ritonavir and dasabuvir (OBV/PTV/r+DSV). HIV/HCV genotype 1 co-infected patients with creatinine levels available at baseline (BL), at the end of treatment (EoT) and after further12 weeks (FU12) were included. A logistic regression model was used to assess the impact of the patients’ characteristics on the reduction of at least 5% in eGFR. A two-way repeated measures mixed model ANOVA analysis with Tuckey post-test was also run.
Globally, 144 HIV/HCV co-infected patients were included, 74% male, with median age of 52 years (48.0-56.5), and median CD4+T-cell count of 658 cells/μl (480-929). Median BL eGFR was 102.0 (90.8-108.1), changing to 99.8 (83.5-104.8) at the EoT, and 100.0 (87.3-105.6) at FU12 (p5% decline, independently from chronological age.